Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$33.0M | -$93.9M | -$66.3M | -$93.9M | -$104M | -$166M |
| Net income | -$33.9M | -$93.0M | -$56.8M | -$95.7M | -$109M | -$184M |
| EPS (diluted) | -$0.13 | -$3.40 | -$1.84 | -$2.44 | -$1.54 | -$2.06 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$23.6M | -$45.8M | -$50.1M | -$64.4M | -$79.1M | -$132M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $80.1M | $134M | $142M | $99.7M | $274M | $258M |
| Total assets | $81.5M | $164M | $170M | $125M | $302M | $440M |
| Total liabilities | $5.65M | $12.3M | $19.1M | $46.4M | $60.7M | $108M |
| Long-term debt | — | — | — | $14.1M | $21.9M | $40.6M |
| Shareholders' equity | $75.9M | $152M | $151M | $78.1M | $241M | $332M |
| Retained earnings | -$44.6M | -$138M | -$194M | -$290M | -$399M | -$583M |
| Shares (wtd avg diluted) | — | 27.4M | 30.9M | 39.2M | 70.5M | 89.3M |
Every figure is extracted from Definium Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.